全文获取类型
收费全文 | 811篇 |
免费 | 35篇 |
国内免费 | 21篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 49篇 |
妇产科学 | 7篇 |
基础医学 | 67篇 |
口腔科学 | 34篇 |
临床医学 | 56篇 |
内科学 | 143篇 |
皮肤病学 | 18篇 |
神经病学 | 65篇 |
特种医学 | 100篇 |
外科学 | 144篇 |
综合类 | 52篇 |
预防医学 | 31篇 |
眼科学 | 22篇 |
药学 | 45篇 |
肿瘤学 | 33篇 |
出版年
2021年 | 6篇 |
2020年 | 5篇 |
2019年 | 8篇 |
2018年 | 16篇 |
2017年 | 7篇 |
2016年 | 11篇 |
2015年 | 14篇 |
2014年 | 18篇 |
2013年 | 36篇 |
2012年 | 22篇 |
2011年 | 33篇 |
2010年 | 34篇 |
2009年 | 34篇 |
2008年 | 20篇 |
2007年 | 49篇 |
2006年 | 44篇 |
2005年 | 21篇 |
2004年 | 35篇 |
2003年 | 16篇 |
2002年 | 22篇 |
2001年 | 18篇 |
2000年 | 23篇 |
1999年 | 16篇 |
1998年 | 26篇 |
1997年 | 32篇 |
1996年 | 41篇 |
1995年 | 22篇 |
1994年 | 13篇 |
1993年 | 21篇 |
1992年 | 8篇 |
1991年 | 11篇 |
1990年 | 9篇 |
1989年 | 25篇 |
1988年 | 11篇 |
1987年 | 14篇 |
1986年 | 13篇 |
1985年 | 14篇 |
1984年 | 12篇 |
1983年 | 9篇 |
1982年 | 7篇 |
1981年 | 6篇 |
1980年 | 11篇 |
1979年 | 8篇 |
1978年 | 3篇 |
1977年 | 7篇 |
1976年 | 10篇 |
1975年 | 8篇 |
1974年 | 4篇 |
1967年 | 2篇 |
1966年 | 2篇 |
排序方式: 共有867条查询结果,搜索用时 250 毫秒
11.
The impact of executive function on response to cognitive behavioral therapy in late‐life depression 下载免费PDF全文
12.
PGE1 accelerates thrombolysis by tissue plasminogen activator 总被引:14,自引:0,他引:14
Platelets are an active element in the generation of thrombus and may influence rates of thrombolysis during the administration of plasminogen activators. To assess the potential importance of platelet aggregation in the thrombolytic response to plasminogen activators, we measured rates of thrombolysis induced by tissue plasminogen activator in the presence and absence of a coinfusion of prostaglandin E1 in a rabbit jugular vein model of thrombosis. Rates of lysis were quantified by measuring the half-time for lysis of the thrombus. At all concentrations of tissue plasminogen activator used, prostaglandin E1 markedly reduced the half-time for clot lysis and enhanced somewhat the overall extent of thrombolysis, without affecting significantly either the degree of fibrinogen depletion or the animals' mean arterial pressures. These effects on thrombolytic efficacy were accompanied by ex vivo evidence of platelet inhibition. These data suggest that the antiplatelet prostaglandin E1 may be a very useful adjunctive agent in thrombolytic therapy primarily by virtue of the significant improvement in the rate of thrombolysis that its use affords. 相似文献
13.
Clinical characteristics,pathophysiology, and management of noncentral nervous system cancer‐related cognitive impairment in adults 下载免费PDF全文
Jeffrey S. Wefel PhD Shelli R. Kesler PhD Kyle R. Noll PhD Sanne B. Schagen PhD 《CA: a cancer journal for clinicians》2015,65(2):123-138
Answer questions and earn CME/CNE Over the past few decades, a body of research has emerged confirming what many adult patients with noncentral nervous system cancer have long reported—that cancer and its treatment are frequently associated with cancer‐related cognitive impairment (CRCI). The severity of CRCI varies, and symptoms can emerge early or late in the disease course. Nonetheless, CRCI is typically mild to moderate in nature and primarily involves the domains of memory, attention, executive functioning, and processing speed. Animal models and novel neuroimaging techniques have begun to unravel the pathophysiologic mechanisms underlying CRCI, including the role of inflammatory cascades, direct neurotoxic effects, damage to progenitor cells, white matter abnormalities, and reduced functional connectivity, among others. Given the paucity of research on CRCI with other cancer populations, this review synthesizes the current literature with a deliberate focus on CRCI within the context of breast cancer. A hypothetical case‐study approach is used to illustrate how CRCI often presents clinically and how current science can inform practice. While the literature regarding intervention for CRCI is nascent, behavioral and pharmacologic approaches are discussed. CA Cancer J Clin 2015;65: 123–138. © 2014 American Cancer Society. 相似文献
14.
15.
16.
17.
18.
19.
B-cell growth factor receptor expression and B-cell growth factor response of leukemic B cell precursors and B lineage lymphoid progenitor cells 总被引:8,自引:1,他引:8
Uckun FM; Fauci AS; Heerema NA; Song CW; Mehta SR; Gajl-Peczalska K; Chandan M; Ambrus JL 《Blood》1987,70(4):1020-1034
The purpose of this study was to analyze the expression of B cell growth factor (BCGF) receptors and to elucidate the biologic effects of biochemically purified natural BCGF at the B cell precursor stage of human B lineage lymphoid differentiation. The specific binding of radioiodinated high-mol-wt BCGF (125I-HMW-BCGF) and low-molecular-wt BCGF (125I-LMW-BCGF) to fresh marrow blasts from B cell precursor acute lymphoblastic leukemia (ALL) patients was initially investigated. The estimated number of radioiodinated BCGF molecules bound per blast ranged from undetectable to 24.3 X 10(3) for HMW-BCGF, and from 11.5 X 10(3) to 457.8 X 10(3) for LMW-BCGF. In 3H-TdR incorporation assays, 75% of cases showed a significant response to LMW-BCGF with a median stimulation index of 9.3. By comparison, only 33% of cases showed a significant response to HMW-BCGF with a median stimulation index of 2.4. Subsequently, B cell precursor colony assays were performed to assess and compare the biologic effects of BCGF on leukemic B lineage lymphoid progenitor cells. Among 28 cases studied, 57% responded to both HMW-BCGF and LMW-BCGF, 21% responded only to LMW-BCGF, and the remaining cases showed no proliferative response to either growth factor. The response patterns of virtually pure populations of FACS- sorted leukemic B cell precursors were essentially identical to the proliferative responses of unsorted leukemic B-cell precursors. Synergistic effects between HMW-BCGF and LMW-BCGF were observed in 80% of the cases that responded to both. The numbers of cell-bound radioiodinated BCGF molecules, the stimulation indices, as well as the number of B cell precursor colonies in BCGF-stimulated cultures showed a marked interpatient variation. Patients with structural chromosomal abnormalities (SCAs) involving 12p11-13 or patients with a Philadelphia chromosome showed a greater HMW-BCGF response at the level of leukemic progenitor cells than did other patients (P = .02). The LMW-BCGF response was significantly greater for patients with SCA than for patients without SCA (P = .04). The response of leukemic progenitor cells to HMW-BCGF or LMW-BCGF did not correlate with sex, age, disease status, FAB morphology, WBC at diagnosis, or immunophenotype. To our knowledge, this study represents the first detailed analyses of BCGF receptor expression and BCGF effects in B cell precursor ALL. The data presented provide direct evidence for the expression of functional receptors for both HMW-BCGF and LMW-BCGF in B cell precursor ALL. 相似文献
20.
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811 总被引:23,自引:13,他引:23
Larson RA; Dodge RK; Burns CP; Lee EJ; Stone RM; Schulman P; Duggan D; Davey FR; Sobol RE; Frankel SR 《Blood》1995,85(8):2025-2037
The goal of this phase II multicenter clinical trial was to evaluate a new intensive chemotherapy program for adults with untreated acute lymphoblastic leukemia (ALL) and to examine prospectively the impact of clinical and biologic characteristics on the outcome. One hundred ninety-seven eligible and evaluable patients (16 to 80 years of age; median, 32 years of age) received cyclophosphamide, daunorubicin, vincristine, prednisone, and L-asparaginase; 167 patients (85%) achieved a complete remission (CR), 13 (7%) had refractory disease, and 17 (9%) died during induction. A higher CR rate was observed in younger patients (94% for those < 30 years old, 85% for those 30 to 59 years old, and 39% for those > or = 60 years old, P < .001) and in those who had a mediastinal mass (100%) or blasts with a T-cell immunophenotype. Eighty percent of B-lineage and 97% of T-cell ALL patients achieved a CR (P = .01). The coexpression of myeloid antigens did not affect the response rate or duration. Seventy percent of those with cytogenetic or molecular evidence of the Philadelphia (Ph) chromosome and 84% of those without such evidence achieved a CR (P = .11). Patients in remission received multiagent consolidation treatment, central nervous system prophylaxis, late intensification, and maintenance chemotherapy for a total of 24 months. After a median follow-up time of 43 months, the median survival for all 197 patients is 36 months; the median remission duration for the 167 CR patients is 29 months. Favorable pretreatment characteristics relative to remission duration or survival are younger age, the presence of a mediastinal mass or lymphadenopathy, a white blood cell count (WBC) less than 30,000/microL, L1 morphology, T or TMy immunophenotype, and the absence of the Ph chromosome. The estimates of the proportion surviving at 3 years are 69% for patients less than 30 years old, 39% for those 30 to 59 years old, 89% for those who had a mediastinal mass, 59% with WBC less than 30,000/microL, 63% with L1 morphology, 69% for T or TMy antigen expression, and 62% for those who lack the Ph chromosome. Fifteen patients (8%) had no unfavorable prognostic factors and have an estimated probability of survival at 5 years of 100% (95% confidence interval, 77% to 100%). This intensive chemotherapy regimen produces a high remission rate and a high proportion of durable remissions in adults with ALL. 相似文献